Antidepressant potential of 5-HT 3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n)

Journal of Young Pharmacists

Volumn 4, Issue 4, 2012, Pages 235-244

  Mahesh, R ^a   Bhatt, S ^a   Devadoss, T ^a   Jindal, A K ^a   Gautam, B K ^a   Pandey, D K ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

forced swim test; head twitch; reserpine; tail suspension test

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; FLUOXETINE; HARMAN; N N PROPYL 3 ETHOXYQUINOXALINE 2 CARBOXAMIDE; PAROXETINE; PARTHENOLIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL TEST; FORCED SWIMMING TEST; GUINEA PIG; HEAD TWITCH; HYPOTHERMIA; IMMOBILIZATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TAIL SUSPENSION TEST;

EID: 84872125357     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.104367     Document Type: Article

References (34)

1. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7:541-7.
2. Nestler EJ, Barrot M, Dileone RJ, Eisch AJ, Gold SJ, Monteggia L. M. Neurobiology of depression. Neuron 2002;34:13-25.
3. Gillespie CF, Nemerof CB. Hypercortisolemia and depression.Psychosom Med 2005;67:S26-8.
4. Charne DS. Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. Am J Psychiatry 2004;161:195-216.
5. Haus U, Spath M, Farber L. Spectrum of use and tolerability of 5-HT3 receptor Antagonists. Scand J Rheumatol 2004;119:12-8.
6. Mahesh R, Perumal RV, Pandi PV. Cancer chemotherapyinduced nausea and vomiting: Role of mediators, development of drugs and treatment methods. Pharmazie 2005;60:83-96.
7. Barnes JM, Barnes NM, Costal B, Ironside JW, Naylor RJ. Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue. J Neurochem 1989;53:1787-93.
8. Abi-Dargham A, Laruelle M, Wong DT, Robertson DW, Weinberger DR, Kleinman JE. Pharmacological and regional characterization of [3H] Y278584 binding sites in human brain. J Neurochem 1993;60:730-7.
9. Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003;461:19-25.
10. Haus U, Varga B, Stratz T, Späth M, Müller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: Influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol Suppl 2000;113:55-8.
11. Faris PL, Eckert ED, Kim SW, Meller WH, Pardo JV, Goodale RL, et al. Evidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms. J Affect Disord 2006;92:79-90.
12. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target? J Psychopharmacol 2010;24:455-69.
13. Hibert MF, Hoffmann R, Miller RC, Carr AA. Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor. J Med Chem 1990;33:1594-600.
14. Mahesh R, Perumal RV, Pandi PV. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1, 8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorg Med Chem Lett 2004;14:5179-81.
15. Bourin M. Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests? Fundam Clin Pharmacol 1990;4:49-64.
16. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32.
17. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
18. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: A new method for screening antidepressant drugs. Psychopharmacology (Berl) 1985;85:367-70.
19. Thierry B, Steru L, Simon P, Porsolt RD. The tail suspension test: Ethical considerations. Psychopharmacology (Berl) 1986;90:284-5.
20. Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzylpiperazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3reeptor antagonist, in animal models of depression. Pharmacol Rep 2010;62:245-57.
21. Kelly JP, Wyrnn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: An an update. Pharmacol Ther 1997;74:299-316.
22. Mahesh R, Bhatt S, Pandey DK, Gautam B. Antidepressant like effect of pimozide in acute and chronic animal models of depression. Ind J Pharm Educ Res 2011;45:46-53.
23. Paton WD, Zar AM. The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 1968;194:13-33.
24. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol 1978;30:312-3.
25. Boissier JR, Simon P. Action de la caféine sur la motilité spontanée de la souris. Arch Int Pharmacodyn Ther 1965;158:212-21.
26. Martin P, Massol J, Soubrie P, Puech AJ. Effects of triiodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches in mice. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:735-48.
27. Ripoll N, David DJ, Dailly E, Hascoët M, Bourin M. Effects in various mice strains in the tail suspension test. Behav Brain Res 2003;143:193-200.
28. Bourin M, Chenu F, Ripoll N, David DJP. A proposal of decision tree to screen putative antidepressants using forced swim and tail suspension tests. Behav Brain Res 2005;164:266-9.
29. Englert LF, Ho BT, Taylor D. The effects of. (-)-delta9- tetrahydrocannabinol on reserpine-induced hypothermia in rats. Br J Pharmacol 1973;49:243-52.
30. Simpson KH, Murphy P, Colthup PV, Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology (Berl) 1992;109:497-8.
31. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2000;113:37-45.
32. Marles RJ, Kaminski J, Arnason JT, Pazos-Sanou L, Heptinstall S, Fischer NH, et al. A bioassay for inhibition of serotonin release from bovine platelets. J Nat Prod 1992;55:1044-56.
33. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B, et al. Parthenolide, an inhibitor of the nuclear factor-B pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002;61:953-63.
34. Van Hoomissen J, Kunrath J, Dentlinger R, Lafrenz A, Krause M, Azar A. Cognitive and locomotor/exploratory behavior after chronic exercise in the olfactory bulbectomy model of depression. Behav Brain Res 2011;222:106-16.